CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0.89×, higher than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score 1.69: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.91%Above 5Y avg (1.06%)
Annual Rate
CNY 0.32Paid semi-annual
Payout Ratio
50.0%Sustainable
Payback Period
41.6 yr
Last Ex-Dividend
May 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.17BCNY620.78M · vs all stocks (USD)
Trailing P/E
35.30xvs Biotechnology peers
Revenue (TTM)
2.95BCNY438.11M · vs all stocks (USD)
Profit Margin
4.19%vs Biotechnology peers
Beta
0.1520xvs all stocks
52-Week Change
-54.45%vs all stocks
Forward Annual Dividend Yield
1.91%vs all stocks
Market Capitalization
4.17BCNY620.78M · vs all stocks (USD)
Enterprise Value
6.01BCNY893.74M · vs all stocks (USD)
Trailing P/E
35.30xvs Biotechnology peers
Forward P/E
11.93xvs Biotechnology peers
Price to Sales (TTM)
1.50xvs Biotechnology peers
Price to Book (MRQ)
1.63xvs Biotechnology peers
Enterprise to Revenue
2.04xvs Biotechnology peers
Enterprise to EBITDA
15.44xvs Biotechnology peers
Gross Margin
20.96%vs Biotechnology peers
Profit Margin
4.19%vs Biotechnology peers
Operating Margin
7.65%vs Biotechnology peers
Return on Assets (TTM)
1.74%vs Biotechnology peers
Return on Equity (TTM)
4.25%vs Biotechnology peers
Revenue (TTM)
2.95BCNY438.11M · vs all stocks (USD)
Revenue per Share (TTM)
11.88CNYUpdated Aug 21, 2026Quarterly Revenue Growth
12.30%vs Biotechnology peers
Gross Profit (TTM)
586.29MCNY87.19M · vs all stocks (USD)
EBITDA (TTM)
398.20MCNY59.22M · vs all stocks (USD)
Net Income (TTM)
123.41MCNY18.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-17.60%vs Biotechnology peers
Operating Cash Flow (TTM)
101.90MCNY15.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-622.54MCNY-92.58M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3200CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.91%vs all stocks
Trailing Annual Dividend Rate
0.4100CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.45%vs all stocks
5-Year Average Dividend Yield
1.06%vs all stocks
Payout Ratio
50.00%vs Biotechnology peers
Minority Interest (Equity)
-14.82MCNYFY2025 · Dec 31, 2025Revenue
2.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.25BCNYFY2025 · Dec 31, 2025Gross Profit
608.62MCNYFY2025 · Dec 31, 2025Operating Income
188.24MCNY27.99M · vs all stocks (USD)
Pre-tax Income
125.56MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.70MCNYFY2025 · Dec 31, 2025Net Income
123.86MCNYFY2025 · Dec 31, 2025EBIT
169.39MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
398.20MCNYFY2025 · Dec 31, 2025Research & Development
151.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
204.44MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
43.83MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
123.86MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.55MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-64.14MCNYFY2025 · Dec 31, 2025Free Cash Flow
-699.67MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
284.12MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
123.86MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.92MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-73.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-163.44MCNYFY2025 · Dec 31, 2025Capital Expenditures
-635.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.82MCNYFY2025 · Dec 31, 2025Sale of Investments
900.00KCNYFY2025 · Dec 31, 2025Other Investing Activity
-6.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-643.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.72BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.19BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-110.81MCNYFY2025 · Dec 31, 2025Other Financing Charges
-10.96MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
409.22MCNYFY2025 · Dec 31, 2025Shares Outstanding
250.12MSharesUpdated Aug 21, 2026Float Shares
156.97MSharesUpdated Aug 21, 2026% Held by Insiders
40.46%vs all stocks
% Held by Institutions
9.45%vs all stocks
Total Cash (MRQ)
446.18MCNY66.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.80CNYUpdated Aug 21, 2026Total Debt (MRQ)
2.37BCNY352.04M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8870xvs Biotechnology peers
Current Ratio (MRQ)
1.21xvs Biotechnology peers
Book Value per Share (MRQ)
10.86CNYUpdated Aug 21, 2026Total Assets
5.77BCNY858.75M · vs all stocks (USD)
Total Current Assets
1.46BCNYFY2025 · Dec 31, 2025Total Liabilities
3.14BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.31BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.80BCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.34BCNYFY2025 · Dec 31, 2025Cash
284.12MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
284.12MCNYFY2025 · Dec 31, 2025Accounts Receivable
271.25MCNYFY2025 · Dec 31, 2025Inventory
532.13MCNYFY2025 · Dec 31, 2025Accounts Payable
712.68MCNYFY2025 · Dec 31, 2025Short-term Debt
486.41MCNYFY2025 · Dec 31, 2025Other Current Liabilities
42.88MCNYFY2025 · Dec 31, 2025Long-term Debt
1.57BCNYFY2025 · Dec 31, 2025Common Stock (Book)
250.12MCNYFY2025 · Dec 31, 2025Retained Earnings
1.14BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.63BCNY391.38M · vs all stocks (USD)
Treasury Stock
50.01MCNYFY2025 · Dec 31, 202552-Week Low
14.52CNYUpdated Aug 21, 202652-Week High
43.60CNYUpdated Aug 21, 202652-Week Change
-54.45%vs all stocks
Beta
0.1520xvs all stocks
50-Day MA
17.57CNYUpdated Aug 21, 2026200-Day MA
28.36CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.35MSharesUpdated Aug 21, 2026Avg 30-Day Volume
6.20MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.5000CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0.89×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 0.89Industry median: 0.07Industry P95: 0.88Peers compared: 258
Financial Health
Altman Z-Score 1.69: grey zoneSignificant
Altman Z-Score: 1.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tilray Brands, Inc.
Tier 1ProductionApproval-Gated PipelineFlowAttention
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Power Solutions International, Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Corcept Therapeutics Incorporated
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Phoenix Education Partners, Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated